Response to Letter to the Editor

Affiliations

¹ Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: mnishio@jfcr.or.jp.
² Genentech, Inc, South San Francisco, California.
³ Department of Medical Oncology, AdventHealth Cancer Institute, Orlando, Florida.

Free article

Comment

Makoto Nishio et al. J Thorac Oncol. 2021 May.

Free article

. 2021 May;16(5):e30-e31.

doi: 10.1016/j.jtho.2021.02.018.

¹ Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: mnishio@jfcr.or.jp.
² Genentech, Inc, South San Francisco, California.
³ Department of Medical Oncology, AdventHealth Cancer Institute, Orlando, Florida.

No abstract available

Comment on

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA. Nishio M, et al. J Thorac Oncol. 2021 Apr;16(4):653-664. doi: 10.1016/j.jtho.2020.11.025. Epub 2020 Dec 14. J Thorac Oncol. 2021. PMID: 33333328 Clinical Trial.
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
Di Federico A, Nuvola G, Deiana C, Donati G, De Giglio A. Di Federico A, et al. J Thorac Oncol. 2021 May;16(5):e29-e30. doi: 10.1016/j.jtho.2021.01.003. J Thorac Oncol. 2021. PMID: 33896575 No abstract available.